flurbiprofen has been researched along with Obesity in 5 studies
Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.
flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The flurbiprofen treatment simultaneously administered." | 5.40 | Therapeutic potential of flurbiprofen against obesity in mice. ( Baba, S; Hosoi, T; Ozawa, K, 2014) |
| "Potential benefits of combining docosahexaenoic acid (DHA), an omega-3 fatty acid with flurbiprofen (Flu), a non-steroidal anti-inflammatory drug in ameliorating obesity remain to be elucidated." | 3.91 | Docosahexaenoic acid-flurbiprofen combination ameliorates metaflammation in rats fed on high-carbohydrate high-fat diet. ( Al-Ashmawy, GM; El-Ashmawy, NE; Kamel, AA, 2019) |
| "Obesity is one of the major risk factors of metabolic syndrome, such as hypertension, hyperlipidemia, and diabetes." | 2.53 | The Mechanisms and Pharmacological Strategy for Treatment of ER Stress-induced Metabolic Syndrome. ( Hosoi, T; Ozawa, K, 2016) |
| "The flurbiprofen treatment simultaneously administered." | 1.40 | Therapeutic potential of flurbiprofen against obesity in mice. ( Baba, S; Hosoi, T; Ozawa, K, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Ashmawy, NE | 1 |
| Al-Ashmawy, GM | 1 |
| Kamel, AA | 1 |
| Hosoi, T | 3 |
| Yamaguchi, R | 1 |
| Noji, K | 1 |
| Matsuo, S | 1 |
| Baba, S | 2 |
| Toyoda, K | 1 |
| Suezawa, T | 1 |
| Kayano, T | 1 |
| Tanaka, S | 1 |
| Ozawa, K | 3 |
| Knadler, MP | 1 |
| Brater, DC | 1 |
| Hall, SD | 1 |
1 review available for flurbiprofen and Obesity
| Article | Year |
|---|---|
The Mechanisms and Pharmacological Strategy for Treatment of ER Stress-induced Metabolic Syndrome.
Topics: Drug Discovery; Endoplasmic Reticulum Stress; Flurbiprofen; Humans; Hypothalamus; Leptin; Metabolic | 2016 |
4 other studies available for flurbiprofen and Obesity
| Article | Year |
|---|---|
Docosahexaenoic acid-flurbiprofen combination ameliorates metaflammation in rats fed on high-carbohydrate high-fat diet.
Topics: Adipose Tissue; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Body Weight; Diet, | 2019 |
Flurbiprofen ameliorated obesity by attenuating leptin resistance induced by endoplasmic reticulum stress.
Topics: Aldehyde Dehydrogenase; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Diet, High-Fat; | 2014 |
Therapeutic potential of flurbiprofen against obesity in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Feasibility Studies; Flurbiprofen; Leptin; Male; M | 2014 |
Plasma protein binding of flurbiprofen: enantioselectivity and influence of pathophysiological status.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Binding, Competitive; Blood Proteins; Flurbiprofen; Humans; | 1989 |